Literature DB >> 26718109

Lung cancer in 2015: Bypassing checkpoints, overcoming resistance, and honing in on new targets.

Egbert F Smit1, Paul Baas1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26718109     DOI： 10.1038/nrclinonc.2015.223

Source DB:  PubMed          Journal:  Nat Rev Clin Oncol        ISSN： 1759-4774            Impact factor:   66.675


× No keyword cloud information.
  9 in total

1.  Heterogeneity Underlies the Emergence of EGFRT790 Wild-Type Clones Following Treatment of T790M-Positive Cancers with a Third-Generation EGFR Inhibitor.

Authors:  Zofia Piotrowska; Matthew J Niederst; Chris A Karlovich; Heather A Wakelee; Joel W Neal; Mari Mino-Kenudson; Linnea Fulton; Aaron N Hata; Elizabeth L Lockerman; Anuj Kalsy; Subba Digumarthy; Alona Muzikansky; Mitch Raponi; Angel R Garcia; Hillary E Mulvey; Melissa K Parks; Richard H DiCecca; Dora Dias-Santagata; A John Iafrate; Alice T Shaw; Andrew R Allen; Jeffrey A Engelman; Lecia V Sequist
Journal:  Cancer Discov       Date:  2015-05-01       Impact factor: 39.397

2.  Response to MET inhibitors in patients with stage IV lung adenocarcinomas harboring MET mutations causing exon 14 skipping.

Authors:  Paul K Paik; Alexander Drilon; Pang-Dian Fan; Helena Yu; Natasha Rekhtman; Michelle S Ginsberg; Laetitia Borsu; Nikolaus Schultz; Michael F Berger; Charles M Rudin; Marc Ladanyi
Journal:  Cancer Discov       Date:  2015-05-13       Impact factor: 39.397

3.  Pembrolizumab for the treatment of non-small-cell lung cancer.

Authors:  Edward B Garon; Naiyer A Rizvi; Rina Hui; Natasha Leighl; Ani S Balmanoukian; Joseph Paul Eder; Amita Patnaik; Charu Aggarwal; Matthew Gubens; Leora Horn; Enric Carcereny; Myung-Ju Ahn; Enriqueta Felip; Jong-Seok Lee; Matthew D Hellmann; Omid Hamid; Jonathan W Goldman; Jean-Charles Soria; Marisa Dolled-Filhart; Ruth Z Rutledge; Jin Zhang; Jared K Lunceford; Reshma Rangwala; Gregory M Lubiniecki; Charlotte Roach; Kenneth Emancipator; Leena Gandhi
Journal:  N Engl J Med       Date:  2015-04-19       Impact factor: 91.245

4.  Rociletinib in EGFR-mutated non-small-cell lung cancer.

Authors:  Lecia V Sequist; Jean-Charles Soria; Jonathan W Goldman; Heather A Wakelee; Shirish M Gadgeel; Andrea Varga; Vassiliki Papadimitrakopoulou; Benjamin J Solomon; Geoffrey R Oxnard; Rafal Dziadziuszko; Dara L Aisner; Robert C Doebele; Cathy Galasso; Edward B Garon; Rebecca S Heist; Jennifer Logan; Joel W Neal; Melody A Mendenhall; Suzanne Nichols; Zofia Piotrowska; Antoinette J Wozniak; Mitch Raponi; Chris A Karlovich; Sarah Jaw-Tsai; Jeffrey Isaacson; Darrin Despain; Shannon L Matheny; Lindsey Rolfe; Andrew R Allen; D Ross Camidge
Journal:  N Engl J Med       Date:  2015-04-30       Impact factor: 91.245

5.  Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer.

Authors:  Julie Brahmer; Karen L Reckamp; Paul Baas; Lucio Crinò; Wilfried E E Eberhardt; Elena Poddubskaya; Scott Antonia; Adam Pluzanski; Everett E Vokes; Esther Holgado; David Waterhouse; Neal Ready; Justin Gainor; Osvaldo Arén Frontera; Libor Havel; Martin Steins; Marina C Garassino; Joachim G Aerts; Manuel Domine; Luis Paz-Ares; Martin Reck; Christine Baudelet; Christopher T Harbison; Brian Lestini; David R Spigel
Journal:  N Engl J Med       Date:  2015-05-31       Impact factor: 91.245

6.  Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer.

Authors:  Hossein Borghaei; Luis Paz-Ares; Leora Horn; David R Spigel; Martin Steins; Neal E Ready; Laura Q Chow; Everett E Vokes; Enriqueta Felip; Esther Holgado; Fabrice Barlesi; Martin Kohlhäufl; Oscar Arrieta; Marco Angelo Burgio; Jérôme Fayette; Hervé Lena; Elena Poddubskaya; David E Gerber; Scott N Gettinger; Charles M Rudin; Naiyer Rizvi; Lucio Crinò; George R Blumenschein; Scott J Antonia; Cécile Dorange; Christopher T Harbison; Friedrich Graf Finckenstein; Julie R Brahmer
Journal:  N Engl J Med       Date:  2015-09-27       Impact factor: 91.245

7.  AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer.

Authors:  Pasi A Jänne; James Chih-Hsin Yang; Dong-Wan Kim; David Planchard; Yuichiro Ohe; Suresh S Ramalingam; Myung-Ju Ahn; Sang-We Kim; Wu-Chou Su; Leora Horn; Daniel Haggstrom; Enriqueta Felip; Joo-Hang Kim; Paul Frewer; Mireille Cantarini; Kathryn H Brown; Paul A Dickinson; Serban Ghiorghiu; Malcolm Ranson
Journal:  N Engl J Med       Date:  2015-04-30       Impact factor: 91.245

8.  Differential Activity of Nivolumab, Pembrolizumab and MPDL3280A according to the Tumor Expression of Programmed Death-Ligand-1 (PD-L1): Sensitivity Analysis of Trials in Melanoma, Lung and Genitourinary Cancers.

Authors:  Luisa Carbognin; Sara Pilotto; Michele Milella; Vanja Vaccaro; Matteo Brunelli; Anna Caliò; Federica Cuppone; Isabella Sperduti; Diana Giannarelli; Marco Chilosi; Vincenzo Bronte; Aldo Scarpa; Emilio Bria; Giampaolo Tortora
Journal:  PLoS One       Date:  2015-06-18       Impact factor: 3.240

9.  Acquired EGFR C797S mutation mediates resistance to AZD9291 in non-small cell lung cancer harboring EGFR T790M.

Authors:  Kenneth S Thress; Cloud P Paweletz; Enriqueta Felip; Byoung Chul Cho; Daniel Stetson; Brian Dougherty; Zhongwu Lai; Aleksandra Markovets; Ana Vivancos; Yanan Kuang; Dalia Ercan; Sarah E Matthews; Mireille Cantarini; J Carl Barrett; Pasi A Jänne; Geoffrey R Oxnard
Journal:  Nat Med       Date:  2015-05-04       Impact factor: 53.440
  9 in total
  4 in total

1.  Development of thyroid dysfunction is associated with clinical response to PD-1 blockade treatment in patients with advanced non-small cell lung cancer.

Authors:  Hye In Kim; Mijin Kim; Se-Hoon Lee; So Young Park; Young Nam Kim; Hosu Kim; Min Ji Jeon; Tae Yong Kim; Sun Wook Kim; Won Bae Kim; Sang-We Kim; Dae Ho Lee; Keunchil Park; Myung-Ju Ahn; Jae Hoon Chung; Young Kee Shong; Won Gu Kim; Tae Hyuk Kim
Journal:  Oncoimmunology       Date:  2017-09-21       Impact factor: 8.110

Review 2.  Present Yourself! By MHC Class I and MHC Class II Molecules.

Authors:  Kenneth L Rock; Eric Reits; Jacques Neefjes
Journal:  Trends Immunol       Date:  2016-09-07       Impact factor: 16.687

3.  Transcriptomic analysis of gene expression in mice treated with troxerutin.

Authors:  Yuerong Wang; Shuangshuang Wei; Lintao Chen; Jinli Pei; Hao Wu; Yechun Pei; Yibo Chen; Dayong Wang
Journal:  PLoS One       Date:  2017-11-30       Impact factor: 3.240

4.  SFTPA1 is a potential prognostic biomarker correlated with immune cell infiltration and response to immunotherapy in lung adenocarcinoma.

Authors:  Lu Yuan; Xixi Wu; Longshan Zhang; Mi Yang; Xiaoqing Wang; Wenqi Huang; Hua Pan; Yuting Wu; Jihong Huang; Wenyu Liang; Jiaxin Li; Xiaodi Zhu; Shuang Wang; Jian Guan; Laiyu Liu
Journal:  Cancer Immunol Immunother       Date:  2021-06-28       Impact factor: 6.968
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.